This article reviews the role of sacubitril/valsartan in the treatment of chronic symptomatic heart failure with reduced ejection fraction following its FDA approval.
The FDA has approved sacubitril/valsartan, an angiotensin-receptor-neprilysin inhibitor, for the treatment of chronic symptomatic heart failure (stage C) in patients with a left ventricular ejection fraction of 35% or less. This article discusses results from a major clinical trial, PARADIGM-HF, and the role of this new drug in heart failure treatment.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: